Spots Global Cancer Trial Database for hormone sensitive prostate cancer
Every month we try and update this database with for hormone sensitive prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer | NCT04995042 | Hormone Sensiti... | SHR7280 | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer | NCT03520478 | Prostate Cancer Hormone-Depende... | SHR3680 Bicalutamide | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Cardiovascular Events in GnRH Agonist vs. Antagonist | NCT04182594 | Hormone Sensiti... Prostate Cancer Cardiac Event | Degarelix GnRH agonist | 18 Years - 90 Years | Rabin Medical Center | |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | NCT02319837 | Hormone Sensiti... Prostate Cancer Cancer of the P... | Enzalutamide Placebo (No lon... Leuprolide Open... | 18 Years - | Pfizer | |
| Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients | NCT06193993 | Prostate Cancer Metastatic Canc... Hormone Sensiti... Castration-resi... | Abiraterone Ace... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer | NCT04220398 | Prostate Cancer Chemotherapy Ef... Hormone Sensiti... Locally Advance... | Neoadjuvant che... Neoadjuvant hor... Radical Prostat... | 18 Years - 75 Years | RenJi Hospital | |
| Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer | NCT04220398 | Prostate Cancer Chemotherapy Ef... Hormone Sensiti... Locally Advance... | Neoadjuvant che... Neoadjuvant hor... Radical Prostat... | 18 Years - 75 Years | RenJi Hospital | |
| Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | NCT04126070 | Hormone Sensiti... Prostate Adenoc... Metastasis Pros... | Androgen Depriv... Nivolumab Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | NCT04126070 | Hormone Sensiti... Prostate Adenoc... Metastasis Pros... | Androgen Depriv... Nivolumab Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC | NCT05983783 | Metastatic Pros... Hormone Sensiti... Chemotherapy Ef... | Docetaxel Rezvilutamide | 40 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer | NCT04995042 | Hormone Sensiti... | SHR7280 | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer | NCT03513211 | Prostate Cancer | SUBA-itraconazo... Hydroxychloroqu... | 18 Years - | St Vincent's Hospital, Sydney |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
